A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Carraway, Hetty E. [2 ]
Germing, Ulrich [3 ]
Wermke, Martin [4 ]
Zeidan, Amer M. [5 ]
Fu, Eric [6 ]
Rueter, Bjoern [7 ]
Burkard, Ute [7 ]
Osswald, Annika [7 ]
Foran, James M. [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA
[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA
[3] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[4] Tech Univ, Med Fac Carl Gustav Carus, NCT UCC ECTU, Dresden, Germany
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT USA
[6] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[7] Boehringer Ingelheim Pharm GmbH & Co KG, Biberach, Germany
[8] Mayo Clin, Dept Hematol & Med Oncol, Jacksonville, FL USA
来源：
HAEMATOLOGICA | 2022年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2742 / 2747
页数：6
相关论文
共 50 条
  • [41] REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients
    Lombardi, G.
    De Salvo, G. L.
    Brandes, A. A.
    Eoli, M.
    Ruda, R.
    Faedi, M.
    Lolli, I.
    Pace, A.
    Rizzato, S.
    Germano, D.
    Pasqualetti, F.
    Farina, M.
    Magni, G.
    Pambuku, A.
    Bergo, E.
    Cabrini, G.
    Indraccolo, S.
    Gardiman, M. P.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
    Scharenberg, Christian
    Giai, Valentina
    Pellagatti, Andrea
    Saft, Leonie
    Dimitriou, Marios
    Jansson, Monika
    Jadersten, Martin
    Grandien, Alf
    Douagi, Iyadh
    Neuberg, Donna S.
    LeBlanc, Katarina
    Boultwood, Jacqueline
    Karimi, Mohsen
    Jacobsen, Sten Eirik W.
    Woll, Petter S.
    Hellstrom-Lindberg, Eva
    HAEMATOLOGICA, 2017, 102 (03) : 498 - 508
  • [43] Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors
    Angevin, Eric
    Elez, Elena
    Cohen, Steven J.
    Van Laethem, Jean-Luc
    Ottensmeier, Christian
    Joly, Florence
    Ray-Coquard, Isabelle
    Lopez-Martin, Jose A.
    Dirix, Luc
    Machiels, Jean-Pascal
    Clive, Sally
    Steven, Neil Matthew
    Reddy, Manjula
    Hall, Brett
    Puchalski, Thomas
    Bandekar, Rajesh
    Van de Velde, Helgi
    Tromp, Brenda J.
    Vermeulen, Jessica
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome
    Garcia-Manero, Guillermo
    Gartenberg, Gary
    Steensma, David P.
    Schipperus, Martin R.
    Breems, Dimitri A.
    de Paz, Raquel
    Valcarcel, David
    Kranenburg, Britte
    Reddy, Manjula
    Komrokji, Rami S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (09) : E156 - E162
  • [45] CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY
    Stemmer, S. M.
    Benjaminov, O.
    Medalia, G.
    Ciuraru, N. B.
    Silverman, M. H.
    Bar-Yehuda, S.
    Fishman, S.
    Harpaz, Z.
    Farbstein, M.
    Cohen, S.
    Patoka, R.
    Singer, B.
    Kerns, W. D.
    Fishman, P.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S555 - S555
  • [46] CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study
    Stemmer, Salomon M.
    Benjaminov, Ofer
    Medalia, Gal
    Ciuraru, Noa
    Silverman, Michael H.
    Bar Yehuda, Sara
    Fishman, Sari
    Harpaz, Zivit
    Farbstein, Motti
    Cohen, Shira
    Petoka, Renana
    Singer, Barak
    Kerns, William D.
    Fishman, Pnina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/ 16)
    Hess, Dagmar
    Colombo, Ilaria
    Haefliger, Simon
    Rabaglio, Manuela
    Bastian, Sara
    Schwitter, Michael
    Eckhardt, Katrin
    Garzon, Jesus Glaus
    Hayoz, Stefanie
    Kopp, Christoph
    Holer, Lisa
    Mc Laughlin, Anna
    Kloft, Charlotte
    Sessa, Cristiana
    Stathis, Anastasios
    Halbherr, Stefan
    Baumgartner, Christian
    Joerger, Markus
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
    Stemmer, Salomon M.
    Benjaminov, Ofer
    Medalia, Gal
    Ciuraru, Noab B.
    Silverman, Michael H.
    Bar-Yehuda, Sara
    Fishman, Sari
    Harpaz, Zivit
    Farbstein, Motti
    Cohen, Shira
    Patoka, Renana
    Singer, Barak
    Kerns, William D.
    Fishman, Pnina
    ONCOLOGIST, 2013, 18 (01): : 25 - 26
  • [49] Azacitidine pretreatment followed by non-myeloablative SCT in patients with high-risk myelodysplastic syndrome: Prospective, open label, multicenter, phase II trial
    Kim, H.
    Jae-Sook, A.
    Kim, Y.
    Min, Y. H.
    Kim, J. S.
    Jang, J. H.
    Jung, C. W.
    Kim, I. H.
    Yoon, H. J.
    Lee, H. G.
    Sohn, S. K.
    Moon, J. H.
    Kim, H.
    Kim, Y. J.
    Won, J. H.
    Bang, S. M.
    Chung, J. S.
    Mun, Y. C.
    LEUKEMIA RESEARCH, 2013, 37 : S151 - S151
  • [50] An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
    Savona, Michael R.
    Odenike, Olatoyosi
    Amrein, Philip C.
    Steensma, David P.
    DeZern, Amy E.
    Michaelis, Laura C.
    Faderl, Stefan
    Harb, Wael
    Kantarjian, Hagop
    Lowder, James
    Oganesian, Aram
    Azab, Mohammad
    Garcia-Manero, Guillermo
    LANCET HAEMATOLOGY, 2019, 6 (04): : E194 - E203
12345